Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of human coagulation factor IX for bleeding control in moderate to severe hemophilia B
CTR20240019Phase 3Completed
- Sponsor
- Pacific Shuanglin Bio-pharmacy
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human coagulation factor IX in hemophilia B (HB), sponsored by Pacific Shuanglin Bio-pharmacy. Started Jan 2024; status: completed.
02
Drugs
human coagulation factor IX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20240019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240019.